Gossamer Bio, Inc.: Opaleye Management Inc. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Opaleye Management Inc. filed an amended Schedule 13G with the SEC disclosing a revised beneficial ownership position in Gossamer Bio, Inc. (accession 0001493152-26-050449). The filing updates the investment manager's previously reported stake in the clinical-stage biopharmaceutical company. Schedule 13G amendments are typically triggered when a passive investor's ownership crosses or adjusts past the 5% threshold, though the headline did not specify the exact percentage or share count. Investors will watch for the precise ownership figures in the full filing to gauge Opaleye's conviction in the name.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Opaleye Management Inc., Gossamer Bio, Inc.